NANO Nanobiotix SA

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:

Jefferies London Healthcare Conference

Date: Monday, November 17, 2025

Time: 3pm GMT / 10am ET / 4pm CET

Location: London, UK

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

The fireside chat will be webcast live from the of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department



Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)

+33 (0) 79 97 29 99







Media Relations


France – HARDY

Caroline Hardy

50







Global – uncapped

Becky Lauer

+1 (646) 286-0057





Attachment



EN
11/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

NANOBIOTIX to Participate in Jefferies London Healthcare Conference PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference: Jefferies London Healthcare ConferenceDate: Monday, November 17, 2025Time: 3pm GMT / 10am ET / 4pm CETLocation: London, UKPresenters: Laurent ...

 PRESS RELEASE

NANOBIOTIX participera à la conférence Jefferies London Healthcare

NANOBIOTIX participera à la conférence Jefferies London Healthcare PARIS et CAMBRIDGE, Mass., 11 nov. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui qu’elle participera à une discussion (« fireside chat ») à la conférence suivante : Jefferies London Healthcare ConferenceDate : lundi 17 novembre 2025Horaire : ...

 PRESS RELEASE

NANOBIOTIX to Participate in Investor Conferences the Week of November...

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: UBS Global Healthcare ConferenceDate: Monday, November 10, 2025Time: 5pm ET / 11pm CETLocation: Palm Beach Gardens, FLPresenter: Bart va...

 PRESS RELEASE

NANOBIOTIX participera à des conférences investisseurs la semaine du 1...

NANOBIOTIX participera à des conférences investisseurs la semaine du 10 novembre PARIS et CAMBRIDGE, Mass., 03 nov. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui qu’elle participera à des discussions (« fireside chat ») aux conférences suivantes : UBS Global Healthcare ConferenceDate : lundi 10 novembre 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch